Lu-Ann Murdoch
ARTICLES BY THIS AUTHOR
- 9/17/2023
Drug news—August 2023
A review of new launches, new indications, new dosage forms and Health Canada advisories. - 9/14/2023
Adding piroxicam improves the efficacy of levonorgestrel emergency contraception
Study shows that adding a cyclo-oxygenase (COX) inhibitor provides a synergistic contraceptive effect to levonorgestrel administered for emergency contraception. - 9/11/2023
Study examines efficacy and tolerability of emerging cough suppressant gefapixant
Study provides insight on the value of a new orally-administered, selective P2X3 receptor antagonist antitussive that is under review by Health Canada. - 9/7/2023
Calcium channel blockers may increase the risk of glaucoma
Calcium channel blockers may be an important modifiable risk factor for glaucoma, possibly through a mechanism that is not related to intraocular pressure. - 9/5/2023
POP QUIZ: Desmopressin for bedwetting
All the following statements about use of desmopressin for monosymptomatic enuresis (bedwetting without any daytime lower urinary tract symptoms) in children are true, EXCEPT for . . . - 9/4/2023
How should enuresis (bedwetting) be managed in children age five or older?
Educate and reassure patients and families that no treatment is necessary for primary monosymptomatic enuresis: nearly all children will outgrow bedwetting with time. - 8/30/2023
Arexvy: first RSV vaccine for older adults expected to be available this fall
The vaccine is used to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age or older. - 8/28/2023
Prevnar 20 now indicated for immunization of infants, children and adolescents
The routine vaccination schedule for prevention of invasive pneumococcal disease is a three-dose primary series followed by a toddler booster dose. - 8/24/2023
POP QUIZ: Rheumatoid arthritis
A person with rheumatoid arthritis has an inadequate response to a first tumour necrosis factor inhibitor, despite good adherence to the therapeutic regimen over the past six months. What should you suggest? - 8/23/2023
Rinvoq approved for use in moderately to severely active ulcerative colitis in adults
A new 45 mg extended-release tablet is expected to be available in mid-September for induction dosing in ulcerative colitis.
